Summary
Cerus: This Blood-Safety Underdog Should Be Earning More Respect
Cerus (CERS) is pivoting toward higher-value therapeutic products while reducing its research cost burden, aided by substantial government funding. Q2 2026 results signal an inflection point: product revenue grew 10%, operating expenses fell 7%, and adjusted EBITDA more than tripled year-over-year. Management raised full-year revenue guidance for the second time this year, now projecting $229–231 million, reflecting growing confidence in commercial momentum.
Cerus Q2 Earnings Call Highlights
Cerus NASDAQ: CERS reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas.
Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis
Cerus' Q1 2026 product revenues grew another 24% YoY. This was mainly thanks to strong platelet demand and rapid IFC adoption. Management raised its 2026 product revenue guidance to $227-$231 million, which would imply promising 10%-12% YoY growth. IFC volumes rose about 120% YoY, making it the clearest current growth vertical beyond platelets.
Cerus Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 792 | $1,276.3 | $1,702.8 | $426.5 | 33.42% |
| NA Nizar Araji National Bank Of Canada /FI/ | 88 | $263.12 | $206.8 | -$56.32 | -21.4% |
| BG Bart Gancher Intech Investment Management LLC | 46,252 | $88,194.88 | $108,692.2 | $20,497.32 | 23.24% |
 John H. Burbank III Passport Capital LLC | 6.4M | $22.12M | $19.12M | -$3M | -13.56% |
 Point72 Asset Management LP Point72 Asset Management LP | 228,172 | $666,261.99 | $682,234.28 | $15,972.29 | 2.4% |
Cerus Corporation (CERS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cerus Corporation ever had a stock split?
Cerus Corporation Profile
| Biotechnology Industry | Healthcare Sector | Vivek K. Jayaraman CEO | NASDAQ (NMS) Exchange | 157085101 CUSIP |
| US Country | 268 Employees | - Last Dividend | - Last Split | 30 Jan 1997 IPO Date |
Overview
Cerus Corporation, established in 1991 and based in Concord, California, positions itself at the forefront of the biomedical products industry with a strong focus on blood safety. The cornerstone of its operations is the development and commercialization of the INTERCEPT Blood System, a proprietary technology designed to enhance the safety of blood transfusions by reducing the presence of blood-borne pathogens in donated blood components. This innovative approach to ensuring blood safety marks Cerus Corporation as a key player in the biomedical sector, catering to an essential need in healthcare systems globally. The company's reach extends beyond the United States, touching markets in Europe, the Commonwealth of Independent States, the Middle East, Latin America, and other international territories through both direct sales forces and distributors.
Products and Services
- INTERCEPT Blood System for Platelets and Plasma: This variant of the INTERCEPT Blood System is specifically designed to inactivate pathogens present in platelets and plasma donated for transfusion purposes. By targeting these components, Cerus Corporation aims to significantly reduce the risk of transmission of blood-borne diseases through transfusions.
- INTERCEPT Blood System for Red Blood Cells: Similar to its counterparts for platelets and plasma, this system is engineered to inactivate pathogens in red blood cells intended for transfusion. Given the essential role of red blood cells in carrying oxygen to the body's tissues, ensuring their safety is critical for patient care.
- INTERCEPT Blood System for Cryoprecipitation: This system utilizes the INTERCEPT plasma system to produce pathogen-reduced cryoprecipitated fibrinogen complex. It is aimed at the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency. This application not only enhances the safety of using cryoprecipitate but also addresses critical medical situations where time and safety are of the essence.
- Pathogen Reduced Plasma, Cryoprecipitate Reduced: By applying its proprietary technology, Cerus Corporation provides pathogen-reduced plasma and cryoprecipitate solutions. These products are pivotal for patient care in situations requiring plasma or fibrinogen complex, further underscoring the company's contribution to safer transfusion practices.
